Guidelines: DEGRO Guidelines (Germany)

From Beacon
Revision as of 13:47, 3 July 2024 by Francine (talk | contribs) (Created page with "{{forproviders}} {{forpolicymakers}} Go back to Germany page '''Primary purpose:''' To establish evidence-based practices for the use of stereotactic radiotherapy and radiosurgery. '''Sponsor, manager or home institution:''' dataOwner::DEGRO. '''Type of information:''' Detailed protocols and evidence-based recommendations for conducting stereotactic radiotherapy and radiosurgery, focusing on specific conditions like brain metastases, early-stage non-small cel...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Go back to Germany page

Primary purpose: To establish evidence-based practices for the use of stereotactic radiotherapy and radiosurgery.

Sponsor, manager or home institution: DEGRO.

Type of information: Detailed protocols and evidence-based recommendations for conducting stereotactic radiotherapy and radiosurgery, focusing on specific conditions like brain metastases, early-stage non-small cell lung cancer (NSCLC), primary and secondary liver cancer, renal and pancreatic cancer, and ventricular tachycardia. These include best practices for treatment planning, dosing, patient selection, and outcomes assessment. medical procedures; diagnosis. Click here to learn more.

Cancer areas of interest: C15-C26: Digestive system cancers; C30-C39: Lung/chest cancers; C69-C72: Eye and brain cancer; C64-C68: Urinary system cancers; C76-C80: Cancers of unknown or unspecified areas. Click here to learn more.

Access to information: Click here to access.

Retrieved from "https://wiki.beaconcancer.org/index.php?title=Guidelines:_DEGRO_Guidelines_(Germany)&oldid=21127"
Powered by MediaWiki
Powered by Semantic MediaWiki